About Claris Bio
Claris Bio is a company based in Jersey City (United States) founded in 2018 by Sunil Chauhan, Clarke Atwell, and Reza Dana. It operates as a HealthTech. Claris Bio has raised $44.5 million across 3 funding rounds from investors including RA Capital, Novo Holdings and Mass General Brigham Ventures. Claris Bio offers products and services including CSB-001. Claris Bio operates in a competitive market with competitors including Ilya Pharma, QBiotics, MediWound, Aurion Biotech and Resolution Therapeutics, among others.
- Headquarter Jersey City, United States
- Founders Sunil Chauhan, Clarke Atwell, Reza Dana
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Claris Biotherapeutics
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$44.5 M (USD)
in 3 rounds
-
Latest Funding Round
$2.3 M (USD), Debt – Conventional
Sep 12, 2025
-
Investors
RA Capital
& 3 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Claris Bio
Claris Bio offers a comprehensive portfolio of products and services, including CSB-001. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
A topical solution for corneal integrity restoration developed.
Funding Insights of Claris Bio
Claris Bio has successfully raised a total of $44.5M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $2.3 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Debt – Conventional — $2.3M
-
First Round
First Round
(28 Dec 2023)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2025 | Amount | Debt – Conventional - Claris Bio | Valuation |
investors |
|
| Feb, 2025 | Amount | Debt – Conventional - Claris Bio | Valuation |
investors |
|
| Dec, 2023 | Amount | Series A - Claris Bio | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Claris Bio
Claris Bio has secured backing from 4 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include RA Capital, Novo Holdings and Mass General Brigham Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Claris Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Claris Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Claris Bio Comparisons
Competitors of Claris Bio
Claris Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ilya Pharma, QBiotics, MediWound, Aurion Biotech and Resolution Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biological drugs for skin and mucosa wound treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules from plant extracts are developed for medical applications.
|
|
| domain | founded_year | HQ Location |
Enzymatic therapies for tissue repair and regeneration are developed.
|
|
| domain | founded_year | HQ Location |
Aurion Biotech is focused on developing advanced therapies for ocular diseases.
|
|
| domain | founded_year | HQ Location |
Macrophage cell therapies are developed for inflammatory and liver diseases.
|
|
| domain | founded_year | HQ Location |
Noninvasive devices and biologics for wound healing are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Claris Bio
Frequently Asked Questions about Claris Bio
When was Claris Bio founded?
Claris Bio was founded in 2018 and raised its 1st funding round 5 years after it was founded.
Where is Claris Bio located?
Claris Bio is headquartered in Jersey City, United States. It is registered at Jersey City, New Jersey, United States.
Who is the current CEO of Claris Bio?
Clarke Atwell is the current CEO of Claris Bio. They have also founded this company.
Is Claris Bio a funded company?
Claris Bio is a funded company, having raised a total of $44.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $44.5M, raised on Dec 28, 2023.
What does Claris Bio do?
Claris Bio is engaged in advancing corneal therapy through innovative biologic solutions. The company operates in the ophthalmology sector, targeting unmet medical needs with a focus on conditions like Limbal Stem Cell Deficiency (LCSD). Their lead program, CSB-001, is developed as a topical ocular biologic using hepatocyte growth factor (HGF) to restore structural and functional corneal integrity. Research and development efforts are supported by robust scientific data and partnerships with institutions like Massachusetts Eye and Ear Infirmary.
Who are the top competitors of Claris Bio?
Claris Bio's top competitors include Ilya Pharma, Aurion Biotech and SanuWave.
What products or services does Claris Bio offer?
Claris Bio offers CSB-001.
Who are Claris Bio's investors?
Claris Bio has 4 investors. Key investors include RA Capital, Novo Holdings, Mass General Brigham Ventures, and Janus Henderson.